The Cancer Drugs Alliance has welcomed tonight’s announcement in the Federal Government Budget, that it will invest $1.6bn in listing new ...
Public submissions to the post-market review of authority required PBS listings closed on Wednesday, 8 October 2014. The public submissions ...
A British-led petition signed by 29,000 people has demanded that Switzerland's Roche, the world's biggest maker of cancer medicines, cut ...
PHARMAC is seeking three new people for its Consumer Advisory Committee. ...
The new pharmacy agreement means consumers overall will pay billions of dollars more for prescribed medicines over the next five ...
Patients with severe gout will soon have a new treatment option as PHARMAC will be funding febuxostat (Adenuric) from 1 ...
Novartis Pharmaceuticals Canada Inc. announced today that Lucentis (ranibizumab), the treatment for several major causes of vision loss, has been approved ...
A stakeholder meeting was held on 4 February 2015 to discuss issues related to a recent submission to the PBAC ...
Bayer Inc. is pleased to announce the Health Canada approval of Nexavar for the treatment of patients with locally advanced ...
NICE has completed a rapid evidence summary on the off-label use of eculizumab (Soliris, Alexion Pharma UK) for managing dense ...
Women with HER2-positive metastatic breast cancer in Manitoba will now be able to access a new treatment option through CancerCare Manitoba. The ...
The fixed dose combination dolutegravir sodium with abacavir sulfate and lamivudine (trade name Triumeq) has been approved since September 2014 for use by ...
ABPI Chief Executive, Stephen Whitehead, comments on the announcement by the Shadow Secretary of State for Health, Andy Burnham MP, ...